ReviewJournal of advanced research2026
Novel protein acylations in Alzheimer's disease: Molecular, mechanisms, biological significance, and diagnostic and therapeutic potentials.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by complex pathogenesis including amyloid-β (Aβ), hyperphosphorylated tau mediated neurofibrillary tangles (NFTs), energy metabolism disorders, and neuroinflammation, imposing significant burdens on patients' families and society. Increasing evidence implicates epigenetic modifications, particularly novel protein acylations, encompassing endogenous energy metabolites- mediated lysine succinylation (Ksucc), propionylation (Kpr), malonylation (Kmal), crotonylation (Kcr), butyrylation (Kbu), 2-hydroxyisobutyrylation (Khib), β-hydroxybutyrylation (Kbhb), and glutarylation (Kglu), lactylation (Kla), alongside benzoylation (Kbz) mediated by sodium benzoate metabolites and isonicotinylation (Kinic) induced by isoniazid, playing a pivotal role in AD pathogenesis. AIM OF REVIEW: To enhance the mechanistic understanding of novel acylations, this review systematically summarizes the molecular biological significance of novel protein acylations and their involvement in AD pathogenesis and improvement. KEY SCIENTIFIC CONCEPTS OF REVIEW: Novel acylations exert profound effects on chromatin architecture, DNA accessibility, and transcriptional regulation. Moreover, they critically coordinate protein properties and functions including modulating protein degradation, protein stability, enzyme activity, protein-protein interaction, and subcellular localization. Dysregulation of specific novel acylations orchestrates key cellular processes such as neuroinflammation, metabolic dysfunction, and programmed cell death, thereby contributing to AD progression. This review systematically delineates the mechanistic foundations of novel acylation modifications and underscores their molecular significance. Furthermore, we comprehensively synthesize current knowledge on the involvement of these acylations in AD, offering novel perspectives for developing targeted preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.